GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Graphite Bio Inc (NAS:GRPH) » Definitions » Piotroski F-Score

GRPH (Graphite Bio) Piotroski F-Score : 0 (As of Jul. 12, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Graphite Bio Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Graphite Bio has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Graphite Bio's Piotroski F-Score or its related term are showing as below:


Graphite Bio Piotroski F-Score Historical Data

The historical data trend for Graphite Bio's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Graphite Bio Piotroski F-Score Chart

Graphite Bio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
N/A N/A 3.00 4.00 3.00

Graphite Bio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 3.00 1.00 1.00 3.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -23.934 + -55.314 + -22.485 + -22.918 = $-124.65 Mil.
Cash Flow from Operations was -21.074 + -13.655 + -9.401 + -45.877 = $-90.01 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(321.902 + 309.996 + 287.044 + 266.228 + 188.456) / 5 = $274.7252 Mil.
Total Assets at the begining of this year (Dec22) was $321.90 Mil.
Long-Term Debt & Capital Lease Obligation was $0.08 Mil.
Total Current Assets was $188.02 Mil.
Total Current Liabilities was $4.80 Mil.
Net Income was -25.835 + -25.936 + -24.682 + -24.599 = $-101.05 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(401.987 + 378.606 + 353.786 + 334.845 + 321.902) / 5 = $358.2252 Mil.
Total Assets at the begining of last year (Dec21) was $401.99 Mil.
Long-Term Debt & Capital Lease Obligation was $1.75 Mil.
Total Current Assets was $275.37 Mil.
Total Current Liabilities was $13.04 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Graphite Bio's current Net Income (TTM) was -124.65. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Graphite Bio's current Cash Flow from Operations (TTM) was -90.01. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-124.651/321.902
=-0.38723276

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-101.052/401.987
=-0.25138126

Graphite Bio's return on assets of this year was -0.38723276. Graphite Bio's return on assets of last year was -0.25138126. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Graphite Bio's current Net Income (TTM) was -124.65. Graphite Bio's current Cash Flow from Operations (TTM) was -90.01. ==> -90.01 > -124.65 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=0.077/274.7252
=0.00028028

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=1.749/358.2252
=0.0048824

Graphite Bio's gearing of this year was 0.00028028. Graphite Bio's gearing of last year was 0.0048824. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=188.021/4.797
=39.19553888

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=275.365/13.043
=21.11209078

Graphite Bio's current ratio of this year was 39.19553888. Graphite Bio's current ratio of last year was 21.11209078. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Graphite Bio's number of shares in issue this year was 8.259. Graphite Bio's number of shares in issue last year was 7.96. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Graphite Bio's gross margin of this year was . Graphite Bio's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=0/321.902
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=0/401.987
=0

Graphite Bio's asset turnover of this year was 0. Graphite Bio's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+1+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Graphite Bio has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Graphite Bio  (NAS:GRPH) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Graphite Bio Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Graphite Bio's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Graphite Bio Business Description

Traded in Other Exchanges
N/A
Address
611 Gateway Boulevard, Suite 210, South San Francisco, CA, USA, 94080
Graphite Bio Inc is a shell company and is actively engaged in the process of a strategic business transaction.
Executives
Kimberlee C Drapkin director PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ecor1 Capital, Llc 10 percent owner 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Samsara Biocapital, L.p. 10 percent owner 628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Phil Gutry officer: CHIEF BUSINESS OFFICER 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Alethia Young officer: Chief Financial Officer C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Versant Ventures Vi Gp, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Matthew Porteus director C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
Katherine V Stultz officer: CHIEF OPERATING OFFICER C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
Abraham Bassan director C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
L.p. 436, 10 percent owner 628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Versant Vantage Ii Gp, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii Gp-gp, Llc 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Vantage Ii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Rizzuto Carlo director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Smital Shah director C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080